» Articles » PMID: 33912645

A Case Series of Aggressive Angiomyxoma: Using Morphologic Type and Hormonal Modification to Tailor Treatment

Overview
Publisher Elsevier
Date 2021 Apr 29
PMID 33912645
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aggressive angiomyxoma is a rare tumour type with a predilection for the female pelvis, high rates of estrogen and progesterone receptor positivity and local recurrence. A retrospective chart review of patients with aggressive angiomyxoma treated at 2 cancer centres is presented. Nine patients were identified with a mean age of 41. Five patients had deeply invasive tumours that were difficult to surgically resect. Four patients had pedunculated tumours with less complex resections. In only two cases was aggressive angiomyxoma considered before resection: one due to classic magnetic resonance imaging findings and one with a preoperative biopsy. Four patients had positive margins after resection, with only one having persistent disease. Two patients were treated with gonadotropin-releasing hormone (GnRH) agonists resulting in tumour regression in one and no recurrence in the other. In this case series, aggressive angiomyxoma presented in deeply invasive and pedunculated forms. Previously reported high rates of recurrence were not observed in this group, perhaps secondary to easier resection in the pedunculated forms. GnRH agonists were successfully used as adjuncts to surgery. Evidence in this case series could be used to provide tailored treatment to patients with aggressive angiomyxoma.

Citing Articles

Aggressive angiomyxoma of the vagina: A case report and literature review.

Yu B, Choi W, Cho D, Lee N Medicine (Baltimore). 2025; 104(4):e41287.

PMID: 39854765 PMC: 11771726. DOI: 10.1097/MD.0000000000041287.


Atypical Vaginal Aggressive Angiomyxoma in a Virgin: A Case Report from South Jordan.

Al-Kharabsheh A, AlTarawneh B, Abufraijeh S, Abu Azzam O Int J Womens Health. 2024; 16:1257-1264.

PMID: 39081286 PMC: 11287368. DOI: 10.2147/IJWH.S465948.


Aggressive angiomyxoma of the pelvis and abdominal wall: Dramatic response to chemical ablation therapy.

Li L, Chuang H, He-Nan L, Dong-Yuan L, Qing-Hua L, Wei L Front Oncol. 2023; 13:1154283.

PMID: 37007152 PMC: 10061005. DOI: 10.3389/fonc.2023.1154283.


Prophylactic oophorectomy and aromatase inhibitors for premenopausal deep angiomyxoma: A case report and literature review.

Tonai N, Nasu K, Yano M, Sato M, Kai K, Nishida M Exp Ther Med. 2022; 25(1):3.

PMID: 36561620 PMC: 9748652. DOI: 10.3892/etm.2022.11702.

References
1.
Siassi R, Papadopoulos T, Matzel K . Metastasizing aggressive angiomyxoma. N Engl J Med. 1999; 341(23):1772. DOI: 10.1056/nejm199912023412315. View

2.
Xu H, Sun P, Xu R, Wang L, Shi Y . Aggressive angiomyxoma in pregnancy: a case report and literature review. J Int Med Res. 2020; 48(7):300060520936414. PMC: 7350053. DOI: 10.1177/0300060520936414. View

3.
Han-Geurts I, van Geel A, van Doorn L, M den Bakker , Eggermont A, Verhoef C . Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery. Eur J Surg Oncol. 2006; 32(10):1217-21. DOI: 10.1016/j.ejso.2006.06.008. View

4.
McCluggage W, Patterson A, Maxwell P . Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity. J Clin Pathol. 2000; 53(8):603-5. PMC: 1762939. DOI: 10.1136/jcp.53.8.603. View

5.
Fuca G, Hindi N, Ray-Coquard I, Colia V, Dei Tos A, Martin-Broto J . Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. Oncologist. 2018; 24(7):e536-e541. PMC: 6656447. DOI: 10.1634/theoncologist.2018-0338. View